SITC 2022 | COM701 & nivolumab in patients with metastatic MSS-CRC & liver metastases

Michael Overman, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of a Phase I (NCT03667716) clinical trial exploring the combination of COM701 plus nivolumab in patients with microsatellite stable colorectal cancer (MSS-CRC) with liver metastases who had exhausted all previous standard therapy or were not eligible to receive standard therapy. COM701 is a monoclonal antibody that binds to PVRIG, inhibiting its interaction with its ligand expressed in tumor cells. Key primary endpoints were safety and tolerability and key secondary endpoints include preliminary antitumor activity and immune-related changes. A total of 22 patients were enrolled, 77% of whom had liver metastases. Overall, overall response rate (ORR) was 9% and ORR was 12% in patients with live metastases. No new safety signals were reported. Conclusively, COM701 plus nivolumab demonstrated preliminary antitumor activity in patients with heavily pretreated metastatic MSS-CRC. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.